Bromide

Bromide

SCHEMBL812599

Cc1cc(C(C)C)c(NCCCNCCNc2c(C(C)C)cc(C)cc2C(C)C)c(C(C)C)c1.[Br-].[Br-].[Co+2]

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CARM1 Q86X55 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL812395 0.97 ALDH1A1 (0.33) ALDH1A1MAPTTDP1L3MBTL1CARM1
Bromide SCHEMBL814643 0.97 ALDH1A1 (0.34) ALDH1A1MAPTTDP1L3MBTL1CARM1
Hydrochloric Acid SCHEMBL814205 0.93 ALDH1A1 (0.34) ALDH1A1MAPTTDP1L3MBTL1CARM1
Bromide SCHEMBL813226 0.93 CARM1 (0.32) CARM1
Hydrochloric Acid SCHEMBL814078 0.90 CARM1 (0.32) CARM1
SCHEMBL814871 0.88 CARM1 (0.33) ALDH1A1MAPTTDP1L3MBTL1CARM1
SCHEMBL814374 0.88 CARM1 (0.33) ALDH1A1MAPTTDP1L3MBTL1CARM1
Hydrochloric Acid SCHEMBL813869 0.88 CARM1 (0.33) ALDH1A1MAPTTDP1L3MBTL1CARM1
SCHEMBL812674 0.88 CARM1 (0.33) ALDH1A1MAPTTDP1L3MBTL1CARM1
SCHEMBL814388 0.88 CARM1 (0.33) ALDH1A1MAPTTDP1L3MBTL1CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058372-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-11-15 US disclosed
US-20080319147-A1 Catalyst Composition II EXXONMOBIL CHEMICAL PATENTS INC. 2008-12-25 US disclosed
US-7371803-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-05-13 US disclosed
US-20070066776-A1 Catalyst composition II SOLAN GREGORY A 2007-03-22 US disclosed
US-7189791-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-03-13 US disclosed
EP-1641842-A2 POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND Exxonmobil Chemical Patents Inc. (US) 2006-04-05 EP disclosed
US-20040266961-A1 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. 2004-12-30 US disclosed
WO-2004106390-A2 POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266961-A1 Catalyst composition II MLX, CBX2, BMX ALDH1A1 4593/4885MAPT 1902/4885TDP1 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.